Inclusion Criteria:

- Man or woman between age 18-65 with newly diagnosed Multiple Myeloma for whom stem
cell transplantation is considered appropriate

- Measurable serum and/or urinary paraprotein

- European Cooperative Oncology Group performance status 0-3

- Serum bilirubin < 1.5x the upper limit of normal (ULN)

- Serum alanine transaminase (ALT)/aspartate transaminase values < 2.5 x ULN

- Subjects (or their legally acceptable representatives) must signed an informed
consent document indicating that they understanding the purpose of and procedures
required for the study and are willing to participate in the study

Exclusion criteria:

- Woman of child bearing potential

- Non-secretory MM

- Serum creatinine > 400 Micromol/l after initial resuscitation

- patients with previous Grade 2-4 peripheral neuropathy

- Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable
dose for at least 3 months before first dose of study drug

- Uncontrolled or severe cardiovascular disease including myocardial infarction within
6 months of enrollment, uncontrolled angina, clinically significant pericardial
disease, or III-IV heart failure